Marek Krzanowski
Research Subjects
Marek Krzanowski has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Pawel Petkow Dimitrow
Department of Cardiology and Cardiovascular Interventions, University Hospital, 30-688 Kraków, Poland
4 shared publications Andrzej Belowski
ANGIO-MEDICUS Angiology Clinic, Kraków, Poland
3 shared publicationsAndrzej Szczeklik
Department of Internal Medicine, Jagiellonian University School of Medicine, 31-501 Kraków, Poland
3 shared publicationsRafał Niżankowski
Department of Angiology, Jagiellonian University Medical College, Krakow, Poland
3 shared publicationsŁukasz Partyka
ANGIO-MEDICUS Angiology Clinic, Kraków, Poland
3 shared publications- Agnieszka Wachsmann
Clinical Department of Angiology, University Hospital in Krakow, 30-688 Krakow, Poland
2 shared publications
Latest Publications
- 1 November 2019
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 7 (6) , 845-852.e2
Posture commonly and considerably modifies stenosis of left common iliac and left renal veins in women diagnosed with pelvic venous disorder
- 1 November 2019
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 7 (6) , 845-852.e2
Posture commonly and considerably modifies stenosis of left common iliac and left renal veins in women diagnosed with pelvic venous disorder
- Top Cited Papers
- 1 September 2019
- Published by Edizioni Minerva Medica in International Angiology
- Vol. 38 (4) , 265-283
Diagnosis and treatment of pelvic congestion syndrome: UIP consensus document
- 1 September 2019
- Published by Edizioni Minerva Medica in International Angiology
- Vol. 38 (4) , 265-283
Top Cited PapersDiagnosis and treatment of pelvic congestion syndrome: UIP consensus document
- Open Access
- 22 February 2019
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 129 (3) , 167-174
Clinical and linguistic validation of the Polish version of VascuQoL, a disease-specific quality of life questionnaire assessing patients with chronic limb ischemia
INTRODUCTION Objective clinical assessments should include patient-reported outcome measures. VascuQoL is an established disease-specific questionnaire assessing the quality of life in patients with peripheral artery disease (PAD). Quality-of-life questionnaires require geographical localization and validation. OBJECTIVES The goal of this study was to validate the Polish version of the VascuQoL: a patient-reported health-related quality-of-life (HRQoL) instrument specific for PAD. PATIENTS AND METHODS The linguistic validation of VascuQoL followed Mapi Institute methodology. Clinical validation process compared VascuQoL, EQ-5D-3L, and SF-36 questionnaires in 100 patients with both intermittent claudication and critical limb-threatening ischemia. Cronbach a coefficients for reliability, receiver operating characteristic curves for clinical discriminative performance, standardized response means for responsiveness, and Pearson correlations for construct validity were evaluated. Additionally, in a separate cohort of 58 patients with stable disease, the test-retest was characterized with intraclass correlation, Bland-Altman analysis, and Pearson correlation coefficients. RESULT VascuQoL proved to perform better than SF-36 and E0.-5D-3L (area under the curve, 0.802). Cronbach a coefficients showed good internal consistency (a values >0.9 for all summary scores). All test-retest Pearson r values for VascuQoL were above 0.70. The intraclass correlation of absolute agreement consistency exceeded 0.8. The Bland-Altman 95% limits of agreement were between 2.72 and 4.87. There were strong and moderate correlations for total scores in all domains between Vasculaol and SF-36, and for most of the domains between VascuQoL and EQ-5D-3L. CONCLUSIONS The Polish version of VascuQoL is a sensitive, accurate, and reliable tool for assessing HRQoL in patients with PAD.
- 22 February 2019
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 129 (3) , 167-174
Open AccessClinical and linguistic validation of the Polish version of VascuQoL, a disease-specific quality of life questionnaire assessing patients with chronic limb ischemia
INTRODUCTION Objective clinical assessments should include patient-reported outcome measures. VascuQoL is an established disease-specific questionnaire assessing the quality of life in patients with peripheral artery disease (PAD). Quality-of-life questionnaires require geographical localization and validation. OBJECTIVES The goal of this study was to validate the Polish version of the VascuQoL: a patient-reported health-related quality-of-life (HRQoL) instrument specific for PAD. PATIENTS AND METHODS The linguistic validation of VascuQoL followed Mapi Institute methodology. Clinical validation process compared VascuQoL, EQ-5D-3L, and SF-36 questionnaires in 100 patients with both intermittent claudication and critical limb-threatening ischemia. Cronbach a coefficients for reliability, receiver operating characteristic curves for clinical discriminative performance, standardized response means for responsiveness, and Pearson correlations for construct validity were evaluated. Additionally, in a separate cohort of 58 patients with stable disease, the test-retest was characterized with intraclass correlation, Bland-Altman analysis, and Pearson correlation coefficients. RESULT VascuQoL proved to perform better than SF-36 and E0.-5D-3L (area under the curve, 0.802). Cronbach a coefficients showed good internal consistency (a values >0.9 for all summary scores). All test-retest Pearson r values for VascuQoL were above 0.70. The intraclass correlation of absolute agreement consistency exceeded 0.8. The Bland-Altman 95% limits of agreement were between 2.72 and 4.87. There were strong and moderate correlations for total scores in all domains between Vasculaol and SF-36, and for most of the domains between VascuQoL and EQ-5D-3L. CONCLUSIONS The Polish version of VascuQoL is a sensitive, accurate, and reliable tool for assessing HRQoL in patients with PAD.
- Open Access
- 22 January 2019
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 77 (1) , 24-32
Dynamics of below-the-knee arterial blood flow after endovascular revascularisation of peripheral arteries as a potential predictor of clinical outcomes during one-year follow-up
Background: Patients with advanced lower limb ischemia are at present, mainly treated using revascularization. Aim: The aim of the study was to investigate whether the dynamics of blood flow in below-the-knee (BTK) arteries assessed at angiogram completion correlate with clinical outcomes after a 12-month follow-up period among patients with severe leg ischemia treated percutaneously. Methods: The current study enrolled 287 consecutive patients who underwent 302 endovascular procedures on the infra-inguinal arteries. The mean age of the included participants was 67.4 ± 10.4 years. After the procedure, blood flow of all patent BTK arteries was assessed using frame count (FC). Patients were then evaluated after 1, 3, 6 and 12 months. During the follow-up visits, clinical condition was evaluated based on the Rutherford scale, ankle-brachial index, the need for reintervention and amputation. Results: Clinical improvement at the end of the follow-up period was observed in 242 cases (80.1%) and no improvement or worsening in 42 (13.0%). In total, 66 reinterventions (21.8%) and 18 (6%) amputations during the follow-up period were recorded. Patients with higher FC on the tibial anterior artery experienced significantly better clinical improvement within the 12-month follow-up period (p = 0.02). Lower FC predisposed to worse clinical outcomes after angioplasty. Similar tendencies were found for the tibial posterior and fibular artery, however, without statistical significance. Conclusions: The results suggest a negative relationship between FC seen on the final angiogram and clinical outcomes in patients undergoing endovascular treatment of the peripheral arteries. Background: Patients with advanced lower limb ischemia are at present, mainly treated using revascularization. Aim: The aim of the study was to investigate whether the dynamics of blood flow in below-the-knee (BTK) arteries assessed at angiogram completion correlate with clinical outcomes after a 12-month follow-up period among patients with severe leg ischemia treated percutaneously. Methods: The current study enrolled 287 consecutive patients who underwent 302 endovascular procedures on the infra-inguinal arteries. The mean age of the included participants was 67.4 ± 10.4 years. After the procedure, blood flow of all patent BTK arteries was assessed using frame count (FC). Patients were then evaluated after 1, 3, 6 and 12 months. During the follow-up visits, clinical condition was evaluated based on the Rutherford scale, ankle-brachial index, the need for reintervention and amputation. Results: Clinical improvement at the end of the follow-up period was observed in 242 cases (80.1%) and no improvement or worsening in 42 (13.0%). In total, 66 reinterventions (21.8%) and 18 (6%) amputations during the follow-up period were recorded. Patients with higher FC on the tibial anterior artery experienced significantly better clinical improvement within the 12-month follow-up period (p = 0.02). Lower FC predisposed to worse clinical outcomes after angioplasty. Similar tendencies were found for the tibial posterior and fibular artery, however, without statistical significance. Conclusions: The results suggest a negative relationship between FC seen on the final angiogram and clinical outcomes in patients undergoing endovascular treatment of the peripheral arteries.
- 22 January 2019
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 77 (1) , 24-32
Open AccessDynamics of below-the-knee arterial blood flow after endovascular revascularisation of peripheral arteries as a potential predictor of clinical outcomes during one-year follow-up
Background: Patients with advanced lower limb ischemia are at present, mainly treated using revascularization. Aim: The aim of the study was to investigate whether the dynamics of blood flow in below-the-knee (BTK) arteries assessed at angiogram completion correlate with clinical outcomes after a 12-month follow-up period among patients with severe leg ischemia treated percutaneously. Methods: The current study enrolled 287 consecutive patients who underwent 302 endovascular procedures on the infra-inguinal arteries. The mean age of the included participants was 67.4 ± 10.4 years. After the procedure, blood flow of all patent BTK arteries was assessed using frame count (FC). Patients were then evaluated after 1, 3, 6 and 12 months. During the follow-up visits, clinical condition was evaluated based on the Rutherford scale, ankle-brachial index, the need for reintervention and amputation. Results: Clinical improvement at the end of the follow-up period was observed in 242 cases (80.1%) and no improvement or worsening in 42 (13.0%). In total, 66 reinterventions (21.8%) and 18 (6%) amputations during the follow-up period were recorded. Patients with higher FC on the tibial anterior artery experienced significantly better clinical improvement within the 12-month follow-up period (p = 0.02). Lower FC predisposed to worse clinical outcomes after angioplasty. Similar tendencies were found for the tibial posterior and fibular artery, however, without statistical significance. Conclusions: The results suggest a negative relationship between FC seen on the final angiogram and clinical outcomes in patients undergoing endovascular treatment of the peripheral arteries. Background: Patients with advanced lower limb ischemia are at present, mainly treated using revascularization. Aim: The aim of the study was to investigate whether the dynamics of blood flow in below-the-knee (BTK) arteries assessed at angiogram completion correlate with clinical outcomes after a 12-month follow-up period among patients with severe leg ischemia treated percutaneously. Methods: The current study enrolled 287 consecutive patients who underwent 302 endovascular procedures on the infra-inguinal arteries. The mean age of the included participants was 67.4 ± 10.4 years. After the procedure, blood flow of all patent BTK arteries was assessed using frame count (FC). Patients were then evaluated after 1, 3, 6 and 12 months. During the follow-up visits, clinical condition was evaluated based on the Rutherford scale, ankle-brachial index, the need for reintervention and amputation. Results: Clinical improvement at the end of the follow-up period was observed in 242 cases (80.1%) and no improvement or worsening in 42 (13.0%). In total, 66 reinterventions (21.8%) and 18 (6%) amputations during the follow-up period were recorded. Patients with higher FC on the tibial anterior artery experienced significantly better clinical improvement within the 12-month follow-up period (p = 0.02). Lower FC predisposed to worse clinical outcomes after angioplasty. Similar tendencies were found for the tibial posterior and fibular artery, however, without statistical significance. Conclusions: The results suggest a negative relationship between FC seen on the final angiogram and clinical outcomes in patients undergoing endovascular treatment of the peripheral arteries.
- 24 December 2018
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 26 (1) , 18-25
PRELUDE Prospective Study of the Serranator Device in the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Popliteal Arteries
Purpose: To evaluate the safety and efficacy of the Serranator Alto PTA Serration Balloon Catheter in subjects with peripheral artery disease in the superficial femoral and popliteal arteries. Materials and Methods: A prospective, multicenter, single-arm feasibility study enrolled 25 patients (mean age 66 years; 18 men) to evaluate Serranator inflation and postinflation effects under monitoring by independent core laboratories. Inclusion criteria were claudication or ischemic rest pain, de novo lesions or native artery restenosis, >70% stenosis, lesion length <10 cm, and a reference vessel diameter of 4 to 6 mm. Chronic total occlusions (CTO) up to 6 cm in length were allowed (n=8). The primary safety endpoint was 30-day major adverse events. Primary efficacy outcome was device success with final diameter stenosis <50%. The secondary objective was to confirm the presence of serrations across the lesions using optical coherence tomography (OCT) or intravascular ultrasound (IVUS) following treatment in a subset of 10 subjects. Follow-up evaluations were conducted at 30 days and 6 months. Results: Technical success of device delivery and retrieval was 100%. The primary safety endpoint was met, with no patients experiencing a major adverse event in the first 30 days. Pretreatment stenosis of 88% was reduced to 23%. One stent was implanted for grade D dissection in a CTO. The core laboratory–adjudicated primary patency was 100% at 1 month and 64% at 6 months. Serrations were confirmed in all 10 OCT/IVUS images reviewed by the core laboratory. The Rutherford category showed significant and sustained improvement at 6 months. Conclusion: The Serranator is a safe and efficacious angioplasty balloon catheter system. This new design provides an exciting potential for optimizing vessel preparation and aiding drug delivery.
- 24 December 2018
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 26 (1) , 18-25
PRELUDE Prospective Study of the Serranator Device in the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Popliteal Arteries
Purpose: To evaluate the safety and efficacy of the Serranator Alto PTA Serration Balloon Catheter in subjects with peripheral artery disease in the superficial femoral and popliteal arteries. Materials and Methods: A prospective, multicenter, single-arm feasibility study enrolled 25 patients (mean age 66 years; 18 men) to evaluate Serranator inflation and postinflation effects under monitoring by independent core laboratories. Inclusion criteria were claudication or ischemic rest pain, de novo lesions or native artery restenosis, >70% stenosis, lesion length <10 cm, and a reference vessel diameter of 4 to 6 mm. Chronic total occlusions (CTO) up to 6 cm in length were allowed (n=8). The primary safety endpoint was 30-day major adverse events. Primary efficacy outcome was device success with final diameter stenosis <50%. The secondary objective was to confirm the presence of serrations across the lesions using optical coherence tomography (OCT) or intravascular ultrasound (IVUS) following treatment in a subset of 10 subjects. Follow-up evaluations were conducted at 30 days and 6 months. Results: Technical success of device delivery and retrieval was 100%. The primary safety endpoint was met, with no patients experiencing a major adverse event in the first 30 days. Pretreatment stenosis of 88% was reduced to 23%. One stent was implanted for grade D dissection in a CTO. The core laboratory–adjudicated primary patency was 100% at 1 month and 64% at 6 months. Serrations were confirmed in all 10 OCT/IVUS images reviewed by the core laboratory. The Rutherford category showed significant and sustained improvement at 6 months. Conclusion: The Serranator is a safe and efficacious angioplasty balloon catheter system. This new design provides an exciting potential for optimizing vessel preparation and aiding drug delivery.
- Open Access
- 24 November 2017
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 107 (4) , 319-328
Myocardial injury after endovascular revascularization in critical limb ischemia predicts 1-year mortality: a prospective observational cohort study
Patients with critical limb ischemia (CLI) are at increased risk of cardiovascular complications and mortality. To determine (1) incidence of myocardial injury following endovascular revascularization, and (2) relationship between myocardial injury with 1-year mortality and major adverse cardiovascular events (MACE; i.e., composite of myocardial infarction, stroke, and death).
- 24 November 2017
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 107 (4) , 319-328
Open AccessMyocardial injury after endovascular revascularization in critical limb ischemia predicts 1-year mortality: a prospective observational cohort study
Patients with critical limb ischemia (CLI) are at increased risk of cardiovascular complications and mortality. To determine (1) incidence of myocardial injury following endovascular revascularization, and (2) relationship between myocardial injury with 1-year mortality and major adverse cardiovascular events (MACE; i.e., composite of myocardial infarction, stroke, and death).
- Top Cited PapersOpen Access
- 1 September 2017
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 10 (9) , e004848
Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency
Background—: Studies assessing drug-coated balloons (DCB) for the treatment of femoropopliteal artery disease are encouraging. However, challenging lesions, such as severely calcified, remain difficult to treat with DCB alone. Vessel preparation with directional atherectomy (DA) potentially improves outcomes of DCB. Methods and Results—: DEFINITIVE AR study (Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency—A Pilot Study of Anti-Restenosis Treatment) was a multicenter randomized trial designed to estimate the effect of DA before DCB to facilitate the development of future end point-driven randomized studies. One hundred two patients with claudication or rest pain were randomly assigned 1:1 to DA+DCB (n=48) or DCB alone (n=54), and 19 additional patients with severely calcified lesions were treated with DA+DCB. Mean lesion length was 11.2±4.0 cm for DA+DCB and 9.7±4.1 cm for DCB ( P =0.05). Predilation rate was 16.7% for DA+DCB versus 74.1% for DCB; postdilation rate was 6.3% for DA+DCB versus 33.3% for DCB. Technical success was superior for DA+DCB (89.6% versus 64.2%; P =0.004). Overall bail-out stenting rate was 3.7%, and rate of flow-limiting dissections was 19% for DCB and 2% for DA+DCB ( P =0.01). One-year primary outcome of angiographic percent diameter stenosis was 33.6±17.7% for DA+DCB versus 36.4±17.6% for DCB ( P =0.48), and clinically driven target lesion revascularization was 7.3% for DA+DCB and 8.0% for DCB ( P =0.90). Duplex ultrasound patency was 84.6% for DA+DCB, 81.3% for DCB ( P =0.78), and 68.8% for calcified lesions. Freedom from major adverse events at 1 year was 89.3% for DA+DCB and 90.0% for DCB ( P =0.86). Conclusions—: DA+DCB treatment was effective and safe, but the study was not powered to show significant differences between the 2 methods of revascularization in 1-year follow-up. An adequately powered randomized trial is warranted. Clinical Trial Registration—: http://www.clinicaltrials.gov . Unique Identifier: NCT01366482.
- 1 September 2017
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 10 (9) , e004848
Top Cited PapersOpen AccessDirectional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency
Background—: Studies assessing drug-coated balloons (DCB) for the treatment of femoropopliteal artery disease are encouraging. However, challenging lesions, such as severely calcified, remain difficult to treat with DCB alone. Vessel preparation with directional atherectomy (DA) potentially improves outcomes of DCB. Methods and Results—: DEFINITIVE AR study (Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency—A Pilot Study of Anti-Restenosis Treatment) was a multicenter randomized trial designed to estimate the effect of DA before DCB to facilitate the development of future end point-driven randomized studies. One hundred two patients with claudication or rest pain were randomly assigned 1:1 to DA+DCB (n=48) or DCB alone (n=54), and 19 additional patients with severely calcified lesions were treated with DA+DCB. Mean lesion length was 11.2±4.0 cm for DA+DCB and 9.7±4.1 cm for DCB ( P =0.05). Predilation rate was 16.7% for DA+DCB versus 74.1% for DCB; postdilation rate was 6.3% for DA+DCB versus 33.3% for DCB. Technical success was superior for DA+DCB (89.6% versus 64.2%; P =0.004). Overall bail-out stenting rate was 3.7%, and rate of flow-limiting dissections was 19% for DCB and 2% for DA+DCB ( P =0.01). One-year primary outcome of angiographic percent diameter stenosis was 33.6±17.7% for DA+DCB versus 36.4±17.6% for DCB ( P =0.48), and clinically driven target lesion revascularization was 7.3% for DA+DCB and 8.0% for DCB ( P =0.90). Duplex ultrasound patency was 84.6% for DA+DCB, 81.3% for DCB ( P =0.78), and 68.8% for calcified lesions. Freedom from major adverse events at 1 year was 89.3% for DA+DCB and 90.0% for DCB ( P =0.86). Conclusions—: DA+DCB treatment was effective and safe, but the study was not powered to show significant differences between the 2 methods of revascularization in 1-year follow-up. An adequately powered randomized trial is warranted. Clinical Trial Registration—: http://www.clinicaltrials.gov . Unique Identifier: NCT01366482.
- 1 February 2016
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 31, 111-123
Costs of Real-Life Endovascular Treatment of Critical Limb Ischemia: Report from Poland—A European Union Country with a Low-Budget Health Care System
- 1 February 2016
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 31, 111-123
Costs of Real-Life Endovascular Treatment of Critical Limb Ischemia: Report from Poland—A European Union Country with a Low-Budget Health Care System
- 1 January 2012
- Vol. 70 (4) , 424
[Angina pectoris due to coronary-subclavian steal syndrome caused by the LIMA graft in the patient after CABG with the use of the right and left mammary artery].
We present a case of a patient with unstable angina pectoris two years after coronary artery by-pass graft surgery with the use of the right and left mammary artery. The symptoms were caused by the critical RIMA stenosis and coronary-subclavian steal syndrome through the LIMA graft. Unsuccessful attempt of percutaneous angioplasty of the closed left subclavian artery was made. The angioplasty of the proximal part of the RIMA with the implantation of a drug eluting stent followed by the angioplasty of both left circumflex artery and obtuse marginal artery with the implantation of bare metal stents was performed. These procedures resulted in disappearance of anginal symptoms. Neurological examination did not reveal any signs of vertebrobasilar steal.
- 1 January 2012
- Vol. 70 (4) , 424
[Angina pectoris due to coronary-subclavian steal syndrome caused by the LIMA graft in the patient after CABG with the use of the right and left mammary artery].
We present a case of a patient with unstable angina pectoris two years after coronary artery by-pass graft surgery with the use of the right and left mammary artery. The symptoms were caused by the critical RIMA stenosis and coronary-subclavian steal syndrome through the LIMA graft. Unsuccessful attempt of percutaneous angioplasty of the closed left subclavian artery was made. The angioplasty of the proximal part of the RIMA with the implantation of a drug eluting stent followed by the angioplasty of both left circumflex artery and obtuse marginal artery with the implantation of bare metal stents was performed. These procedures resulted in disappearance of anginal symptoms. Neurological examination did not reveal any signs of vertebrobasilar steal.
- 1 October 2010
- Published by International Society of Endovascular Specialists in Journal of Endovascular Therapy
- Vol. 17 (5) , 633-641
Express LD Vascular Stent in the Treatment of Iliac Artery Lesions: 24-Month Results From the MELODIE Trial
Purpose: To report the 2-year results of the MELODIE trial, which evaluated the safety and effectiveness of the balloon-expandable Express LD Vascular stent for the treatment of atherosclerotic iliac artery disease. Methods: This prospective, multicenter, single-arm trial enrolled 151 patients (113 men; mean age 60.1±8.4 years) with 163 de novo or restenotic iliac lesions. The primary endpoint, 6-month angiographic mean percent loss of luminal diameter, was compared to an objective performance criterion (OPC) based on published results with the Palmaz stent. Follow-up included ankle-brachial index (ABI) measurement and symptom assessment (Fontaine classification) at discharge, 30 days, and 6, 12, and 24 months. Arteriography was performed at 6 months and computed tomographic angiography (CTA) at 1 and 2 years. Results: The primary endpoint of 6-month mean percent luminal diameter loss was 16.2% (upper 95% confidence boundary of 19.1%) and non-inferior to the 20% OPC (p=0.006). Primary patency was 92.1% at 6 months and 87.8% at 2 years. The rate of major adverse events (MAE) was 6.3% at 6 months and 10.2% at 2 years. Of the 3 event types included in the definition of MAE, only target lesion revascularization occurred; no distal embolization or device- or procedure-related deaths were recorded. The percent of patients with Fontaine stage IIb symptoms or worse improved from 84.1% before the procedure to 16.8% at 2 years (pConclusion: The Express LD Vascular stent is safe, effective, and non-inferior to the Palmaz stent for treatment of iliac artery stenosis.
- 1 October 2010
- Published by International Society of Endovascular Specialists in Journal of Endovascular Therapy
- Vol. 17 (5) , 633-641
Express LD Vascular Stent in the Treatment of Iliac Artery Lesions: 24-Month Results From the MELODIE Trial
Purpose: To report the 2-year results of the MELODIE trial, which evaluated the safety and effectiveness of the balloon-expandable Express LD Vascular stent for the treatment of atherosclerotic iliac artery disease. Methods: This prospective, multicenter, single-arm trial enrolled 151 patients (113 men; mean age 60.1±8.4 years) with 163 de novo or restenotic iliac lesions. The primary endpoint, 6-month angiographic mean percent loss of luminal diameter, was compared to an objective performance criterion (OPC) based on published results with the Palmaz stent. Follow-up included ankle-brachial index (ABI) measurement and symptom assessment (Fontaine classification) at discharge, 30 days, and 6, 12, and 24 months. Arteriography was performed at 6 months and computed tomographic angiography (CTA) at 1 and 2 years. Results: The primary endpoint of 6-month mean percent luminal diameter loss was 16.2% (upper 95% confidence boundary of 19.1%) and non-inferior to the 20% OPC (p=0.006). Primary patency was 92.1% at 6 months and 87.8% at 2 years. The rate of major adverse events (MAE) was 6.3% at 6 months and 10.2% at 2 years. Of the 3 event types included in the definition of MAE, only target lesion revascularization occurred; no distal embolization or device- or procedure-related deaths were recorded. The percent of patients with Fontaine stage IIb symptoms or worse improved from 84.1% before the procedure to 16.8% at 2 years (pConclusion: The Express LD Vascular stent is safe, effective, and non-inferior to the Palmaz stent for treatment of iliac artery stenosis.